Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 6/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.48 |
| ▸ | HRH1 | P35367 | 3/20 | 0.48 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
| ▸ | MC3R | P41968 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13961538 | 0.87 | CYP3A4 (0.49) | SIGMAR1LMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL23873425 | 0.85 | LMNA (0.69) | LMNACYP3A4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL5030029 | 0.82 | CYP3A4 (0.60) | SIGMAR1LMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL5030031 | 0.82 | CYP3A4 (0.60) | SIGMAR1LMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL25641449 | 0.78 | CYP3A4 (0.45) | SIGMAR1LMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL11871057 | 0.77 | SLC6A2 (0.68) | SIGMAR1LMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL8185372 | 0.76 | SIGMAR1 (0.50) | SIGMAR1LMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL15908333 | 0.76 | SIGMAR1 (0.50) | SIGMAR1LMNACYP3A4CYP1A2CYP2D6 | |
| Prothixene SCHEMBL623020 | 0.76 | SLC6A2 (0.76) | SIGMAR1LMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL3939116 | 0.76 | ALDH1A1 (0.65) | SIGMAR1LMNACYP3A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2744808-A2 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | Mount Sinai School of Medicine (US) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013025882-A2 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2013-02-21 | — | — | WO | disclosed |
| EP-1837381-B1 | Ink-jet recording ink set and ink-jet recording method | FUJIFILM CORP (JP) | 2011-03-02 | — | — | EP | disclosed |
| WO-2008118164-A1 | COMPOUNDS TO PROMOTE REGENERATION OF BONE MARROW | ZOLTAN LABORATORIES LLC (US) | 2008-10-02 | — | — | WO | disclosed |
| US-20070238725-A1 | Therapeutic combinations for the treatment or prevention of psychotic disorders | WYETH (US) | 2007-10-11 | — | — | US | disclosed |
| US-20060258639-A1 | Therapeutic combinations for the treatment or prevention of psychotic disorders | WYETH (US) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258639-A1 | Therapeutic combinations for the treatment or prevention of psychotic disorders | TTPA, GAP43, SLC6A3 | SIGMAR1 1680/4885LMNA 1941/4885CYP3A4 4055/4885 |
| US-20070238725-A1 | Therapeutic combinations for the treatment or prevention of psychotic disorders | SLC6A3, GRIN2A, GRIN2C | SIGMAR1 475/4885LMNA 2152/4885CYP3A4 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.